Steady improvement of prothrombin levels after cyclophosphamide therapy in pediatric lupus anticoagulant hypoprothrombinemia syndrome (LAHPS).
Lupus anticoagulant hypoprothrombinemia syndrome (LAHPS) is a rare acquired disorder associated with several different conditions but mostly with systemic lupus erythematosus (SLE). LAHPS probably results from the presence of anti-Factor II antibodies, which usually counterbalance the prothrombotic effect of the lupus anticoagulant (LAC). In fact, Factor II deficiency in SLE is invariably associated with the presence of LAC. No consensus exists for the treatment of LAHPS. Corticosteroids, with or without the addition of vitamin K or blood products, have been a successful first-line treatment. Immunoglobulin (IVIG) treatment has been shown to be effective in the setting of acute bleeding. However, in some patients, conservative treatment is not enough to control bleeding, and the addition of immunosuppressive therapy, usually azathioprine, is needed. In our patients, Factor II deficiency reappeared after tapering steroids. Both children achieved normal Factor II levels with cyclophosphamide. This effect was long-lasting, a phenomenon that has not been documented in children prior to this report.
Taddio
Andrea
A
Department of Sciences of Reproduction and Development, University of Trieste, IRCCS Burlo Garofolo, Istituto per l'Infanzia, via dell'Istria 65/1, Trieste, 34100, Italy.|Division of Rheumatology, A.I. duPont Hospital for Children, Department of Paediatrics, Thomas Jefferson University, 1600 Rockland Road, Wilmington, DE, 19803, USA.
Brescia
AnneMarie C
AC
Division of Rheumatology, A.I. duPont Hospital for Children, Department of Paediatrics, Thomas Jefferson University, 1600 Rockland Road, Wilmington, DE, 19803, USA.
Lepore
Loredana
L
Department of Sciences of Reproduction and Development, University of Trieste, IRCCS Burlo Garofolo, Istituto per l'Infanzia, via dell'Istria 65/1, Trieste, 34100, Italy.
Rose'
Carlos D
CD
Division of Rheumatology, A.I. duPont Hospital for Children, Department of Paediatrics, Thomas Jefferson University, 1600 Rockland Road, Wilmington, DE, 19803, USA. crose@nemours.org.
D000293:Adolescent; D015415:Biomarkers / Q000097:blood; D002648:Child; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007020:Hypoprothrombinemias / Q000097:blood* / Q000188:drug therapy / Q000209:etiology; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008297:Male; D011516:Prothrombin / Q000378:metabolism*; D013577:Syndrome
D015415:Biomarkers; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011516:Prothrombin